Psychometric evaluation of the COPD assessment test: Data from the BREATHE study in the Middle East and North Africa region - 04/01/13
on behalf of the BREATHE study groupA
Summary |
The objective of this study was to assess the validity and performance of the Arabic and Turkish versions of the COPD Assessment Test (CAT) for evaluating the severity and impact of COPD symptoms. The data were obtained from the BREATHE study in the Middle East and North Africa region, a large general population survey of COPD conducted in ten countries of the region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), using a standardised methodology. A total of 62,086 subjects were screened, of whom a random sample of 5,681 subjects were administered the CAT by telephone. 5,639 evaluable questionnaires were recovered, representing a completion rate of 99%. In addition, the CAT was administered to an additional 833 subjects fulfilling the epidemiological diagnostic criteria for COPD. Mean scores in the general population were 6.99±6.91 for the Arabic version and 9.88±9.04 for the Turkish version. In patients with COPD, mean scores were 16.2±9.1 and 20.9±10.2 respectively. Scores were consistently higher in smokers than in non-smokers. In the general population, the proportion of respondents fulfilling criteria for COPD rose with higher CAT scores, and particularly above the 80th percentile, where 63% of COPD cases were to be found. This suggests that the CAT may be useful as a case-finding tool in the general population. In the COPD population, healthcare resource consumption rose linearly with CAT score above a threshold score of twenty, arguing in favour of the good criterion validity of the CAT. The internal consistency of the CAT was high (Cronbach’s ⍺ 0.85 for the Arabic and 0.86 for the Turkish versions) and the factorial structure was unidimensional. In conclusion, this study performed in Arabic and Turkish speaking populations confirms the utility and validity of the CAT as a simple tool to collect data on the severity and impact of COPD symptoms, and suggests that it may potentially be useful as a case-finding tool to identify people at risk for COPD in the general population.
Le texte complet de cet article est disponible en PDF.Keywords : COPD assessment Test, CAT, COPD, Middle East, North Africa, BREATHE study
Plan
| Conflict of interest statement AE-H and NR are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD. AL is a director of MS Health, the clinical and epidemiological research company responsible for the implementation, the collection of data and the statistical analysis of the results of the BREATHE study. AD is a director of Foxymed, a medical communication and consultancy company who participated in the exploration and interpretation of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories. CN advised on the data management and statistical analysis of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories. NS has received honoraria from GlaxoSmithKline Laboratories for his contribution to the BREATHE study. PJ has received lecture and consulting fees and research grants from GSK, but received no fees in relation to the BREATHE study. |
Vol 106 - N° S2
P. S86-S99 - décembre 2012 Retour au numéro
Article précédent
- Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa: The BREATHE study
- Mehmet Polatli, Ali Ben Kheder, Siraj Wali, Arshad Javed, Adel Khattab, Bassam Mahboub, Ghali Iraqi, Chakib Nejjari, Samya Taright, Marie-Louise Koniski, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?